Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients with Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial
- Nizar M. Tannir
- , Neeraj Agarwal
- , Camillo Porta
- , Nicola J. Lawrence
- , Robert Motzer
- , Bradley McGregor
- , Richard J. Lee
- , Rohit K. Jain
- , Nancy Davis
- , Leonard J. Appleman
- , Oscar Goodman
- , Walter M. Stadler
- , Sunil Gandhi
- , Daniel M. Geynisman
- , Roberto Iacovelli
- , Begoña Mellado
- , Juan Manuel Sepúlveda Sánchez
- , Robert Figlin
- , Thomas Powles
- , Lalith Akella
- University of Texas MD Anderson Cancer Center
- University of Utah
- University of Pavia
- University of Bari
- The University of Auckland
- Memorial Sloan-Kettering Cancer Center
- Dana-Farber Cancer Institute
- Massachusetts General Hospital
- University of South Florida
- Vanderbilt University
- University of Pittsburgh
- Las Vegas Municipal
- University of Chicago
- Florida Cancer Specialists
- Fondazione Policlinico Universitario A. Gemelli IRCCS
- University of Barcelona
- Hospital Universitario 12 de Octubre
- Cedars-Sinai Medical Center
- Barts Health NHS Trust
- Université Paris-Sud
- Calithera Biosciences
Research output: Contribution to journal › Article › peer-review
112
Scopus
citations